RESUMEN
Sympathetic vascular transduction is commonly understood to act as a basic relay mechanism, but under basal conditions, competing dilatory signals may interact with and alter the ability of sympathetic activity to decrease vascular conductance. Thus, we determined the extent to which spontaneous bursts of muscle sympathetic nerve activity (MSNA) mediate decreases in forearm vascular conductance (FVC) and the contribution of local α-adrenergic receptor-mediated pathways to the observed FVC responses. In 19 young men, MSNA (microneurography), arterial blood pressure and brachial artery blood flow (duplex Doppler ultrasound) were continuously measured during supine rest. These measures were also recorded in seven men during intra-arterial infusions of normal saline, phentolamine (PHEN) and PHEN with angiotensin II (PHEN+ANG). The latter was used to control for increases in resting blood flow with α-adrenergic blockade. Spike-triggered averaging was used to characterize beat-by-beat changes in FVC for 15 cardiac cycles following each MSNA burst and a peak response was calculated. Following MSNA bursts, FVC initially increased by +3.3 ± 0.3% (P = 0.016) and then robustly decreased to a nadir of -5.8 ± 1.6% (P < 0.001). The magnitude of vasoconstriction appeared graded with the number of consecutive MSNA bursts; while individual burst size only had a mild influence. Neither PHEN nor PHEN+ANG infusions affected the initial rise in FVC, but both infusions significantly attenuated the subsequent decrease in FVC (-2.1 ± 0.7% and -0.7 ± 0.8%, respectively; P < 0.001 vs. normal saline). These findings indicate that spontaneous MSNA bursts evoke robust beat-by-beat decreases in FVC that are exclusively mediated via α-adrenergic receptors.
Asunto(s)
Antebrazo/fisiología , Receptores Adrenérgicos alfa/fisiología , Descanso/fisiología , Antagonistas Adrenérgicos alfa/farmacología , Adulto , Angiotensina II/farmacología , Antebrazo/irrigación sanguínea , Humanos , Masculino , Fentolamina/farmacología , Flujo Sanguíneo Regional/efectos de los fármacos , Vasoconstrictores/farmacología , Adulto JovenRESUMEN
Deficiency of long-chain 3-hydroxyacyl-coenzyme A (CoA) dehydrogenase (LCHADD) is a rare inborn error of metabolism. It is associated with hypertrophic cardiomyopathy and less frequently with dilated cardiomyopathy. The incidence and pathophysiology of cardiac involvement in LCHADD is poorly understood. This report describes the acute decompensation of a 3-year-old girl who had LCHADD with rapidly developing dilated cardiomyopathy. A review of the literature and possible causes of cardiomyopathy in LCHADD are explored.
Asunto(s)
Acil-CoA Deshidrogenasa de Cadena Larga/deficiencia , Cardiomiopatía Dilatada/enzimología , Cardiomiopatía Dilatada/genética , Enfermedad Aguda , Preescolar , Femenino , HumanosRESUMEN
OBJECTIVE: The purpose of this study was to evaluate the role of cardiac computed tomography (CT) in the care of adults with congenital heart disease (CHD). METHODS: A retrospective analysis of adult patients with CHD who underwent cardiac CT from April 2005 to May 2006 was performed. Data collected included diagnosis, presence or absence of cardiac symptoms, presence or absence of a pacemaker or defibrillator, anatomic and functional abnormalities, and the need for subsequent surgical or transcatheter intervention based on cardiac CT findings. RESULTS: Eighty-seven adult patients with CHD underwent cardiac CT during this period. Fifty-four subjects had cardiac CT findings that warranted possible transcatheter or surgical interventions or both. Of these, 30 patients went on to transcatheter or surgical intervention based on cardiac CT results. Twenty (37%) subjects of the study population had either pacemaker or implantable cardioverter defibrillator. CONCLUSIONS: Cardiac CT provides important volumetric imaging information to guide management in adult patients with CHD.
Asunto(s)
Cardiopatías Congénitas/diagnóstico por imagen , Cardiopatías Congénitas/cirugía , Adulto , Femenino , Humanos , Masculino , Selección de Paciente , Pronóstico , Radiografía , Reproducibilidad de los Resultados , Estudios Retrospectivos , Sensibilidad y EspecificidadRESUMEN
OBJECTIVE: The purpose of this study was to assess the association of calcium replacement therapy with morbidity and mortality in infants after cardiac surgery involving cardiopulmonary bypass. DESIGN: Retrospective chart review. SETTING: The cardiac intensive care unit at a tertiary care children's hospital. PATIENTS: Infants undergoing cardiac surgery involving cardiopulmonary bypass between October 2002 and August 2004. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Total calcium replacement (mg/kg calcium chloride given) for the first 72 postoperative hours was measured. Morbidity and mortality data were collected. The total volume of blood products given during the first 72 hrs was recorded. Infants with confirmed chromosomal deletions at the 22q11 locus were noted. Correlation and logistic regression analyses were used to generate odds ratios and 95% confidence intervals, with p < .05 being significant. One hundred seventy-one infants met inclusion criteria. Age was 4 +/- 3 months and weight was 4.9 +/- 1.7 kg at surgery. Six infants had deletions of chromosome 22q11. Infants who weighed less required more calcium replacement (r = -.28, p < .001). Greater calcium replacement correlated with a longer intensive care unit length of stay (r = .27, p < .001) and a longer total hospital length of stay (r = .23, p = .002). Greater calcium replacement was significantly associated with morbidity (liver dysfunction [odds ratio, 3.9; confidence interval, 2.1-7.3; p < .001], central nervous system complication [odds ratio, 1.8; confidence interval, 1.1-3.0; p = .02], infection [odds ratio, 1.5; confidence interval, 1.0-2.2; p < .04], extracorporeal membrane oxygenation [odds ratio, 5.0; confidence interval, 2.3-10.6; p < .001]) and mortality (odds ratio, 5.8; confidence interval, 5.8-5.9; p < .001). Greater calcium replacement was not associated with renal insufficiency (odds ratio, 1.5; confidence interval, 0.9-2.3; p = .07). Infants with >1 sd above the mean of total calcium replacement received on average fewer blood products than the total study population. CONCLUSIONS: Greater calcium replacement is associated with increasing morbidity and mortality. Further investigation of the etiology and therapy of hypocalcemia in this population is warranted.
Asunto(s)
Suplementos Dietéticos/efectos adversos , Cardiopatías/epidemiología , Calcio , Puente Cardiopulmonar/efectos adversos , Femenino , Cardiopatías/mortalidad , Cardiopatías/cirugía , Humanos , Lactante , Recién Nacido , Masculino , Periodo Posoperatorio , Estudios RetrospectivosRESUMEN
OBJECTIVE: Hyperglycemia in critical care populations has been shown to be a risk factor for increased morbidity and mortality. Minimal data exist in postoperative pediatric cardiac patients. The goal of this study was to determine whether hyperglycemia in the postoperative period was associated with increased morbidity or mortality. DESIGN: Retrospective chart review. SETTING: Tertiary care, free-standing pediatric medical center with a dedicated cardiac intensive care unit. PATIENTS: We included 184 patients <1 yr of age who underwent cardiac surgery requiring cardiopulmonary bypass from October 2002 to August 2004. Patients with a weight <2 kg, a preoperative diagnosis of diabetes, preoperative extracorporeal membrane oxygenation support, solid organ transplant recipients, and preoperative renal or liver insufficiency were excluded. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Age was 4.3 +/- 3.2 months and weight was 4.9 +/- 1.7 kg at surgery. Duration of hyperglycemia was significantly longer in patients with renal insufficiency (p = .029), liver insufficiency (p = .006), infection (p < .002), central nervous system event (p = .038), extracorporeal membrane oxygenation use (p < .001), and death (p < .002). Duration of hyperglycemia was also significantly associated with increased intensive care (p < .001) and hospital (p < .001) stay and longer ventilator use (p < .001). Peak glucose levels were significantly different in patients with renal insufficiency (p < .001), infection (p = .002), central nervous system event (p = .01), and mortality (p < .001). CONCLUSIONS: Hyperglycemia in the postoperative period was associated with increased morbidity and mortality in postoperative pediatric cardiac patient. Strict glycemic control may improve outcomes in this patient population.
Asunto(s)
Procedimientos Quirúrgicos Cardíacos , Puente Cardiopulmonar , Hiperglucemia , Cuidados Posoperatorios , Procedimientos Quirúrgicos Cardíacos/efectos adversos , Procedimientos Quirúrgicos Cardíacos/mortalidad , Puente Cardiopulmonar/efectos adversos , Puente Cardiopulmonar/mortalidad , Femenino , Cardiopatías Congénitas/cirugía , Humanos , Hiperglucemia/epidemiología , Hiperglucemia/etiología , Hiperglucemia/prevención & control , Lactante , Recién Nacido , Modelos Logísticos , Masculino , Análisis Multivariante , Ohio/epidemiología , Complicaciones Posoperatorias/epidemiología , Complicaciones Posoperatorias/mortalidad , Estudios Retrospectivos , Riesgo , Medición de RiesgoRESUMEN
Heparin induced thrombocytopenia (HIT) is a rare, but potentially life-threatening complication of heparin therapy. In patients with HIT, alternative means of anticoagulation are necessary. The authors present an infant with HIT who required anticoagulation during cardiopulmonary bypass for tricuspid valve excision in the treatment of bacterial endocarditis. The direct thrombin inhibitor, argatroban, was successfully used. Previous reports regarding the use of argatroban and other nonheparin anticoagulants for anticoagulation are reviewed and suggestions regarding argatroban dosing in infants are presented.
Asunto(s)
Anticoagulantes/uso terapéutico , Puente Cardiopulmonar , Heparina/efectos adversos , Ácidos Pipecólicos/uso terapéutico , Antibacterianos/uso terapéutico , Anticuerpos/análisis , Anticoagulantes/administración & dosificación , Anticoagulantes/efectos adversos , Arginina/análogos & derivados , Hipersensibilidad a las Drogas , Endocarditis Bacteriana/complicaciones , Endocarditis Bacteriana/cirugía , Heparina/inmunología , Hepatomegalia , Humanos , Lactante , Complicaciones Intraoperatorias , Masculino , Ácidos Pipecólicos/administración & dosificación , Esplenomegalia , Sulfonamidas , Trombocitopenia/complicaciones , Válvula Tricúspide/cirugíaRESUMEN
Arginine vasopressin is a peptide produced in the posterior pituitary whose primary physiologic role is fluid homeostasis. Recent investigations have demonstrated a therapeutic role for arginine vasopressin in adult cardiac arrest as well as adult and pediatric vasodilatory shock. We review the physiology of arginine vasopressin and examine the supporting data behind the developing clinical applications of this naturally produced peptide.